{"entity":{"id":"neo-811","kind":"drug","name":"NEO-811","aka":["NEO811"],"tldr":"NEO-811 is an experimental molecular glue degrader from Neomorph, in phase 1 trials for clear cell renal cell carcinoma.","summary":"NEO-811 (NEO811) is a molecular glue degrader (cereblon-dependent) from Neomorph. An investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signalling pathway in clear cell renal cell carcinoma; the pipeline page names the target as ARNT/HIF-1beta. Its furthest stage is phase 1, for clear cell renal cell carcinoma. ClinicalTrials.gov registers it in one study linked below. First patient dosed in phase 1/2 NEO-811-101 (NCT07300241), announced 3 Feb 2026; registry lists PHASE1, recruiting. Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Neomorph: neomorph.com","url":"https://neomorph.com/pipeline/"},{"label":"Neomorph: neomorph.com","url":"https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/"},{"label":"Neomorph: neomorph.com","url":"https://neomorph.com/press-release/neomorph-announces-first-patient-dosed-in-phase-1-2-trial-evaluating-neo-811-for-the-treatment-of-locally-advanced-or-metastatic-non-resectable-clear-cell-renal-cell-carcinoma/"},{"label":"ClinicalTrials.gov: trials of NEO-811","url":"https://clinicaltrials.gov/search?intr=NEO-811"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["clear-cell-rcc"],"sections":[],"technologies":[],"targets":["arnt"],"drugs":[],"companies":["neomorph"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07300241"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"NEO-811","modality":"Molecular glue degrader (cereblon-dependent)","mechanism":"An investigational molecular glue degrader designed to induce targeted degradation of a key disease-driving protein and fully block a central signalling pathway in clear cell renal cell carcinoma; the pipeline page names the target as ARNT/HIF-1beta.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/neo-811/","neighbours":{"cancer":[{"id":"clear-cell-rcc","kind":"cancer","name":"Clear cell renal cell carcinoma","route":"/cancers/clear-cell-rcc/"}],"target":[{"id":"arnt","kind":"target","name":"ARNT","route":"/targets/arnt/"}],"company":[{"id":"neomorph","kind":"company","name":"Neomorph","route":"/companies/neomorph/"}],"trial":[{"id":"nct07300241","kind":"trial","name":"Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma","route":"/trials/nct07300241/"}]}}